$KALV Reports Positive Results for KVD900 Phase 2
$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) –
– KVD900 Generally Safe and Well-Tolerated –
There were no serious adverse events reported in the trial and no patients withdrew due to adverse events.
finance.yahoo.com/ne...sults-113000067.html
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) –
– KVD900 Generally Safe and Well-Tolerated –
There were no serious adverse events reported in the trial and no patients withdrew due to adverse events.
finance.yahoo.com/ne...sults-113000067.html